2026-04-17T00:56:44Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1641222025-12-04T21:41:44Zcom_2072_1057col_2072_478917col_2072_478933

00925njm 22002777a 4500 dc Sierra Ortigosa, Josep Maria author Fusté i Domínguez, Ester author Rabanal Anglada, Francesc author Vinuesa Aumedes, Teresa author Viñas, Miquel author 2020-06-03T09:21:22Z 2020-06-03T09:21:22Z 2017-04-11 2020-06-03T09:21:23Z INTRODUCTION: The recent dramatic increase in the incidence of antimicrobial resistance has been recognized by organizations such as the United Nations and World Health Organization as well as the governments of the USA and several European countries. A relatively new weapon in the fight against severe infections caused by multi-drug resistant bacteria is antimicrobial peptides (AMPs). These include colistin, currently regarded as the last line of antimicrobial therapy against multi-drug resistant microorganisms. Areas covered: Here, the authors provide an overview of the current research on AMPs. The focus is AMPs currently being developed for the treatment of recalcitrant bacterial infections, the synergies of AMPs and antibiotics, and the activity of AMPs against biofilm. This review also includes a brief introduction into the use of AMPs in infections caused by Mycobacterium, fungi, and parasites. Expert opinion: In research into new antimicrobials, AMPs are gaining increasing attention. While many are natural and are produced by a wide variety of organisms, others are being newly designed and chemically synthesized in the laboratory to achieve novel antimicrobial agents. The same strategy to fight infections in nature is thus being effectively exploited to safeguard human and animal health. Antibiòtics Pèptids Resistència als medicaments Espectrometria de masses Antibiotics Peptides Drug resistance Mass spectrometry An overview of antimicrobial peptides and the latest advances in their development